Similar articles

• Intensive versus moderate lipid lowering with statins after acute coronary syndromes.

  Paradis JM, LeLorier J. Paradis JM, et al. N Engl J Med. 2004 Aug 12;351(7):714-7; author reply 714-7. N Engl J Med. 2004. PMID: 15309744 No abstract available.
• [Atorvastatin in the treatment of high risk patients with ischemic heart disease and dyslipidemia. Safety assessment in the Russian Multicenter Study ATLANTIKA].

  Mareev VIu. Mareev VIu. Kardiologiia. 2010;50(9):4-14. Kardiologiia. 2010. PMID: 21118160 Clinical Trial. Russian. No abstract available.
• Cost-effectiveness of high-dose atorvastatin compared with usual-dose simvastatin: less than IDEAL?

  Kaul P. Kaul P. Eur Heart J. 2007 Jun;28(12):1405-6. doi: 10.1093/eurheartj/ehm168. Epub 2007 Jun 6. Eur Heart J. 2007. PMID: 17553925 No abstract available.
• [Efficacy of atorvastatin in long-term treatment of patients with ischemic heart disease].

  Belousov IuB, Leonova MV. Belousov IuB, et al. Kardiologiia. 2003;43(4):14-7. Kardiologiia. 2003. PMID: 12968598 Review. Russian. No abstract available.
• Fixed combination of amlodipine and atorvastatin in cardiovascular risk management: patient perspectives.

  Devabhaktuni M, Bangalore S. Devabhaktuni M, et al. Vasc Health Risk Manag. 2009;5(1):377-87. doi: 10.2147/vhrm.s3339. Vasc Health Risk Manag. 2009. PMID: 19475775 Free PMC article. Review.